Millipore — Merger or Acquisition (March 2010)
22 slides from Millipore's merger presentation, Mar 3, 2010
Slide 1: Schedule 14A Proxy Statement - Millipore Corporation
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S
Slide 2: Town Hall Meeting
On March 3, 2010, Millipore Corporation held a town hall meeting concerning the proposed transaction with Merck KGaA. A copy of the presentation that was used in connection with the meeting and posted on its intranet follows: Town Hall Meeting March 3, 2010
Slide 3: Agenda
Agenda Ø Welcome and Introduction - Martin Madaus, Chairman, President & CEO, Millipore Ø Merck Overview - Dr. Karl-Ludwig Kley, Chairman of the Executive Board, Merck KGaA 2
Slide 4: Merck KGaA & Millipore
Merck KGaA & Millipore MILLIPORE Merc ADVANCING LIFE SCIENCE TOGETHER™ Research. Development. Production. MILLIPORE
Slide 5: Creating a world-class partner to the Life Science sector
Creating a world-class partner to the Life Science sector March 3, 2010
Slide 6: Cautionary Statements
Cautionary Statements – Merck does not assume any responsibility with respect to the completeness and the accuracy of the information contained in this document (the "Information"). The Information is selective and does not purport to contain all information the addressee may require. This document
Slide 7: A compelling opportunity for Merck and Millipore
A compelling opportunity for Merck and Millipore • Creates a US$ 2.9 billion (EUR 2.1 billion) world- class partner for the Life Science sector Contributes complementary high-margin specialty products with an attractive growth profile Significant scale in high-growth bioscience and bioproduction seg
Slide 8: Merck at a glance
Merck at a glance Total revenues by Business Company Description Sector (FY09) • Founded in 1668 Chemicals • Headquarters: Darmstadt, Germany 25% • Around 33,000 employees in 61 countries 75% • Shareholder structure: 70% Merck family Pharma via general partner E. Merck KG; 30% publicly traded Total
Slide 9: Corporate structure
Corporate structure Merck Group Pharmaceuticals Chemicals Merck Serono Liquid Crystals Performance & Consumer Health Care Life Science Chemicals Central functions
Slide 10: Performance & Life Science Chemicals Laboratory Business
Performance & Life Science Chemicals Laboratory Business Chemical Food & & Water Industry Testing Beverage Pharma & Academia Biopharma Laboratory Business • Availability of global network of own subsidiaries and exclusive dealers ensures customer proximity • Serving approximately 1 million customers
Slide 11: Performance & Life Science Chemicals Life Science Solutions
Performance & Life Science Chemicals Life Science Solutions Biopharma Cosmetics Pharma Food Life Science Solutions Life Science Solutions serves the pharmaceutical, biopharmaceutical, cosmetics and food industry. The product portfolio covers: • Products and services for the entire value chain of bio
Slide 12: Merck U.S. business overview
Merck U.S. business overview We operate in North America under the umbrella brand EMD, formed from the initials of Emanuel Merck, Darmstadt. Since 1917, Merck & Co. has been an independent company. EMD Chemicals EMD Serono Headquarter: Gibbstown, NJ • Headquarter: Rockland, MA • Approx. 1,000 employ
Slide 13: Merck commitment to invest in Millipore
Merck commitment to invest in Millipore • Commitment to invest in Millipore’s operations and to grow and develop Millipore’s talented workforce – Proven commitment to Billerica and the region with significant investment in last years • Commitment to maintain and build upon Millipore’s existing commu
Slide 14: "Best of both worlds" approach
“Best of both worlds” approach • Transaction is about combining our strengths, not cost synergies • Intention to retain the senior management team • Merck to build on successful acquisition and integration track record • Merck to apply “best of both worlds” integration approach across all operating
Slide 15: Transforming Merck's chemicals business
Transforming Merck’s chemicals business MILLIPORE MERCK Total FY09 Sales: EUR 1.2bn Total CHEMICALS FY09 Sales: EUR 1.9bn (1) Bioscience Laboratory Merck Millipore Business EUR EUR 1.2bn Pro-forma FY09 Sales 0.9bn (2) EUR 2.1bn Bioprocess Pigments Performance EUR Chemicals Pro-forma FY09 Sales: 1.1b
Slide 16: Scale in high-growth market segments
Scale in high-growth market segments Projected Research Customers FY09 sales in EURm(1) market segment growth(2) • Bioscience customers: Critical mass, broad product portfolio and (3) Bioscience 77 310 386 6-10% strong specialized sales force • Lab customers: High-quality chemicals and water purific
Slide 17: Beyond Chemicals - Covering the entire value chain for biopharma and pharma customers
Beyond Chemicals - Covering the entire value chain for biopharma and pharma customers Merck Millipore • Bioscience kits and reagents Biopharma Value Chain • Process monitoring Creating an integrated solutions offering to biopharma customers tools • Services Upstream- Downstream- Biodiscovery Formula
Slide 18: Strong global market presence
Strong global market presence Sales by region in EURm(1) for FY09 897 • Enhanced presence in the U.S. 479 737 • Adds scale to sales and 475 431 marketing 418 262 236 • Stronger partner to global Europe 195 Americas customers • Critical mass in India and China Millipore Merck Note: (1) Exchange Rate
Slide 19: Enhanced distribution capabilities
Enhanced distribution capabilities • Combined bioscience business to benefit from Millipore’s strong e-commerce platform − Drives sales and profitability − Enhances operational efficiency and simplifies processes • Larger sales force leads to greater customer proximity – Strengthened specialty sales
Slide 20: Combined R&D capacity creates powerful innovation platform
Combined R&D capacity creates powerful innovation platform R&D expenses (EUR m and % sales) 10.1% Life Technologies 240 • Pro forma annual R&D budget Thermo 2.4% of US$ 167m (EUR 123m) FisherScientific 177 focused on products for pharma Merck 5.9% and biotech customers Millipore 123 Millipore 6.9% •
Slide 21: What you can expect in the coming months
What you can expect in the coming months • Closing subject to Millipore shareholder approval, antitrust clearance and other customary closing conditions • Until closing, our businesses remain separate and independent – Closing expected in 2H 2010 – Only designated people should be contacting Merck c
Slide 22: Questions?
‘ MERCK SSS QUESTIONS?